Graduate studies at Western
Journal of Business Ethics Education 2 (1):123-132 (2005)
|Abstract||The (B) case summarizes GSK’s response to pressures to increase access to essential medicines in developing countries and subsequent developments|
|Keywords||No keywords specified (fix it)|
No categories specified
(categorize this paper)
|Through your library||Configure|
Similar books and articles
N. Craig Smith & Anne Duncan (2005). GlaxoSmithKline and Developing Country Access to Essential Medicines (A). Journal of Business Ethics Education 2 (1):97-121.
Joo-Young Lee & Paul Hunt (2012). Human Rights Responsibilities of Pharmaceutical Companies in Relation to Access to Medicines. Journal of Law, Medicine and Ethics 40 (2):220-233.
Nicole Hassoun (2012). Global Health Impact: A Basis for Labeling and Licensing Campaigns? Developing World Bioethics 12 (3):121-134.
Devi Sridhar (2008). Improving Access to Essential Medicines: How Health Concerns Can Be Prioritised in the Global Governance System. Public Health Ethics 1 (2):83-88.
Klaus M. Leisinger (2009). Corporate Responsibilities for Access to Medicines. Journal of Business Ethics 85 (1):3 - 23.
Richard E. Ashcroft (2005). Access to Essential Medicines: A Hobbesian Social Contract Approach. Developing World Bioethics 5 (2):121–141.
Matthew Rimmer (2008). Race Against Time: The Export of Essential Medicines to Rwanda. Public Health Ethics 1 (2):89-103.
Rudolf V. van Puymbroeck (2010). Basic Survival Needs and Access to Medicines – Coming to Grips with TRIPS: Conversion + Calculation. Journal of Law, Medicine and Ethics 38 (3):520-549.
Robert C. Bird (2009). Developing Nations and the Compulsory License: Maximizing Access to Essential Medicines While Minimizing Investment Side Effects. Journal of Law, Medicine and Ethics 37 (2):209-221.
Anand Grover, Brian Citro, Mihir Mankad & Fiona Lander (2012). Pharmaceutical Companies and Global Lack of Access to Medicines: Strengthening Accountability Under the Right to Health. Journal of Law, Medicine and Ethics 40 (2):234-250.
Klaus M. Leisinger (2012). Poverty, Disease, and Medicines in Low- and Middle-Income Countries. Business and Professional Ethics Journal 31 (1):135-185.
Debora Diniz (2009). Rationing the Access to High Cost Medicines in Developing Countries. Developing World Bioethics 9 (2).
Michael Ravvin (2008). Incentivizing Access and Innovation for Essential Medicines: A Survey of the Problem and Proposed Solutions. Public Health Ethics 1 (2):110-123.
W. Pinxten, H. Nys & K. Dierickx (2010). Access to Investigational Medicinal Products for Minors in Europe: Ethical and Regulatory Issues in Negotiating Children's Access to Investigational Medicines. Journal of Medical Ethics 36 (12):791-794.
Matthew Lee & Jillian Kohler (2010). Benchmarking and Transparency: Incentives for the Pharmaceutical Industry's Corporate Social Responsibility. [REVIEW] Journal of Business Ethics 95 (4):641-658.
Added to index2012-03-18
Total downloads3 ( #213,563 of 739,308 )
Recent downloads (6 months)1 ( #61,243 of 739,308 )
How can I increase my downloads?